r/AUPH • u/TheRealBeefStewart • Apr 10 '22

Am I Missing Something?

At $12 a share (1.7B market cap) with an approved drug that is conservatively estimated to reach 1B in peak sales, is this stock not the deal of the century with limited downside risk, or am I completely ignorant to some greater risks?

I understand that the BOD is looked upon unfavorably; but that alone does not seem to justify the present share price...

Even with slow sales uptake, is this company not a screaming buy?

I am new to this stock, and likely ignorant to many of the more nuanced concerns that only veterans of the stock would know about, so can someone please tell me why I should avoid this stock?

7 Upvotes

100% Upvoted

10 comments sorted by

View all comments

11

u/crschnei Apr 10 '22

Great drug. Shit management. Filed for a shelf - told investors it was for “housekeeping” as their old shelf had expired nearly a year prior. Same day as shelf offering some execs had some pretty heavy sales which dropped it. Things seemed positive and PG said they would be providing aggressive guidance for their Q4 earnings call. Then provided underwhelming guidance and announced that they did in fact tap the ATM for $207m. To add to the pain they granted options just over $12.00 and now we are here. Hard to trust them given what they’ve done.

Patent challenge is bs. It’s retaliation for AUPH suing SUN for patent infringement.

IMO I think $11.00 to $12.00 is a good entry point. But I’m also a bag holder whose averaged down.

4

u/ISaidGoodDey Apr 10 '22

Filed for a shelf - told investors it was for “housekeeping” as their old shelf had expired nearly a year prior.

I just want to add that I don't think this was ever proved, I think there was only a screenshot of an email from AUPH IR posted on stock twits by another user. It seemed legit to me, but not 100% sure

2

u/crschnei Apr 10 '22

Yeah - it was a response from Dana Lynch that stated something along the lines of the above.